Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | CFD | P00746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616458 | 0.84 | HSD17B10 (0.61) | HPGDKDM4EALDH1A1CFDGAA | |
| SCHEMBL8837258 | 0.81 | ALDH1A1 (0.55) | HPGDKDM4EALDH1A1CFDGAA | |
| SCHEMBL690246 | 0.79 | KDM4E (0.53) | HPGDKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL10536973 | 0.78 | KDM4E (0.51) | HPGDKDM4EALDH1A1KMT2AMEN1 | |
| Ammonia Solution, Strong SCHEMBL10539920 | 0.78 | KDM4E (0.51) | HPGDKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL4650357 | 0.78 | KMT2A (0.59) | HPGDKDM4EALDH1A1GAAKMT2A | |
| Methylamine SCHEMBL5383831 | 0.76 | AGTR1 (0.50) | HPGDKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL7529131 | 0.76 | GAA (0.59) | HPGDKDM4EALDH1A1GAAKMT2A | |
| SCHEMBL6814215 | 0.76 | CA12 (0.70) | HPGDKDM4EALDH1A1GAACA12 | |
| SCHEMBL12608931 | 0.75 | RXFP1 (0.54) | HPGDKDM4EALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373300-B1 | NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-05-20 | — | — | EP | claimed |
| EP-2035029-B1 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS | UCB PHARMA GMBH (DE) | 2016-11-30 | — | — | EP | disclosed |
| US-9446011-B2 | Anticonvulsant combination therapy | UCB PHARMA GMBH (CZ) | 2016-09-20 | — | — | US | disclosed |
| US-9308183-B2 | Therapy for hyperexcitability disorders | UCB PHARMA GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| EP-2992891-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BRIVARACETAM AND LACOSAMIDE WITH SYNERGISTIC ANTICONVULSANT EFFECT | UCB Pharma GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-9095557-B2 | Anticonvulsant combination therapy | UCB PHARMA GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20150202184-A1 | ANTICONVULSANT COMBINATION THERAPY | SCHWARZ PHARMA AG (DE) | 2015-07-23 | — | — | US | disclosed |
| US-8828943-B2 | Anticonvulsant combination therapy | UCB PHARMA GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-2046386-B1 | PEPTIDE COMPOUNDS FOR THE TREATMENT OF SKELETAL MUSCLE DISORDERS ASSOCIATED WITH ION CHANNEL DYSFUNCTION | UCB PHARMA GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8735356-B2 | Anticonvulsant combination therapy | UCB PHARMA GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-5654301-A | Lacosamide FDA Orange book listed patent | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-08-05 | — | — | US | disclosed |
| US-5378729-A | Diamide derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0592490-A4 | AMINO ACID DERIVATIVE ANTICONVULSANT | RES CORP TECHNOLOGIES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0592490-A1 | AMINO ACID DERIVATIVE ANTICONVULSANT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1992021648-A1 | AMINO ACID DERIVATIVE ANTICONVULSANT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0194464-B1 | AMINO ACID DERIVATIVES AND USE THEREOF FOR THE PREPARATION OF AN ANTICONVULSANT | Research Corporation Technologies, Inc. (a Delaware corp.) (US) | 1991-04-03 | — | — | EP | disclosed |
| WO-1990015069-A2 | AMINO ACID DERIVATIVE ANTICONVULSANT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1990-12-13 | — | — | WO | disclosed |
| EP-0400440-A1 | Amino acid derivative anticonvulsant | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0263506-A2 | Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0194464-A1 | Amino acid derivatives and use thereof for the preparation of an anticonvulsant | Research Corporation Technologies, Inc. (a Delaware corp.) (US) | 1986-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202184-A1 | ANTICONVULSANT COMBINATION THERAPY | VIP, GABRE, GABRB2 | HPGD 1944/4885KDM4E 3721/4885ALDH1A1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.